A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Trial ID or NCT#
NCT01572519
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.
Official Title
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Patients with histopathologically confirmed initial diagnosis of Hodgkin lymphoma and who have disease that has relapsed or is refractory that is progressing or active and requires treatment after at least 1 appropriate therapy
Exclusion Criteria:
- - Known brain metastases or leptomeningeal disease - Other malignancy within past 5 years - Has any condition that, in the opinion of the investigator, would make study participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments - QTc prolongation at screening or other factors that increase the risk of QT prolongation such as diagnosis or family history of long-QT syndrome, diagnosed or suspected congenital long QT syndrome, or concomitant use of medication that can prolong the QT interval - Taking CYP3A4 substrate drugs with a narrow therapeutic index (eg, alfentanil, astemizole, sirolimus, tacrolimus, terfenadine)
Investigator(s)
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
Contact
Sarah Daadi
650-725-6456
View on ClinicalTrials.gov
